Patent intelligence · US
US 12049520
Bicyclic peptide ligands specific for CD137
Bicyclic peptide ligands specific for CD137
Patent details — US 12049520
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jul 30, 2024
- Expiration
- Jul 25, 2044
- Applicant
- BicycleTx Limited
- Claims
- 24
- CPC classes
- A61K, A61K38/00, A61K47/64
Quick answer
US 12049520 (Bicyclic peptide ligands specific for CD137) is held by BicycleTx Limited. Status: granted. Granted Jul 30, 2024. Expires Jul 25, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BicycleTx Limited
- Grant date
- Expiration
- Claims
- 24
- CPC classes
- A61K, A61K38/00, A61K47/64
More from BicycleTx Limited
Related pharmaceutical patents in our USPTO index.
-
US 12378288
Multimeric bicyclic peptide ligands
granted -
US 12377155
Bicyclic peptide ligands specific for PSMA
granted -
US 12350343
Bicyclic peptide ligands specific for MT1-MMP
granted -
US 12318454
Bicyclic peptide ligands specific for MT1-MMP
granted -
US 12150998
Bicyclic peptide ligands specific for P-selectin
granted -
US 11970555
Bicyclic peptide ligands specific for transferrin receptor 1 (TfR1)
granted -
US 11970553
Heterotandem bicyclic peptide complex
granted
Frequently asked questions
What is US patent 12049520?
US 12049520 (Bicyclic peptide ligands specific for CD137) is held by BicycleTx Limited. Status: granted. Granted Jul 30, 2024. Expires Jul 25, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12049520?
BicycleTx Limited is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 57 pharmaceutical patents for this assignee.
When does US 12049520 expire?
Our index shows an expiration date of Jul 25, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.